The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years who do not respond adequately to antihistamines. This expands Dupixent’s prior approval for older patients and marks it as the first targeted therapy for young children with CSU in the EU. The approval is based on clinical trial data showing significant reduction in itch and hives, with a safety profile consistent with previous uses. Dupixent’s approval offers a new treatment option for young children suffering from this chronic inflammatory skin condition, potentially improving their quality of life.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
